On March 2, 2025 BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, reported its participation in the 22nd Annual Meeting of the Japanese Society of Medical Oncology (JSMO2025) from March 6–8, 2025, in Kobe, Japan (Press release, BostonGene, MAR 2, 2025, View Source [SID1234650791]). This premier conference is dedicated to advancing precision oncology and fostering collaboration among global oncology experts.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

BostonGene will present research demonstrating how its AI-powered multiomics platform transforms cancer biology understanding and enhances treatment selection by integrating multi-scale, multi-modal data analysis.

During the event, Nathan Fowler, MD, Chief Medical Officer at BostonGene, will deliver a keynote presentation titled "Cutting Edge of Genomic Medicine and Novel Therapy in Hematologic Malignancies." Dr Fowler will highlight how BostonGene, in collaboration with renowned clinical partners, leverages multiomics techniques to identify biomarker predictors of treatment success, driving the next evolution of drug development.

Thursday, March 6 | 8:30 AM – 10:00 AM JST
Symposium 3 – Room 4
Oral presentations

Multiomic clustering of cutaneous melanoma patients to reveal survival trends based on tumor immune evasion features:

The presentation highlights BostonGene’s innovative approach of combining genomic and transcriptomic data to identify tumor immune microenvironment patterns linked to survival in patients with cutaneous melanoma.

Saturday, March 8 | 8:30 AM – 9:30 AM JST
Unraveling sarcomatoid features in clear cell renal cell carcinoma with RNA-seq:

This presentation will showcase the value of predictive modeling in developing targeted therapy to treat clear cell renal carcinoma, emphasizing BostonGene’s Tumor PortraitTM test in identifying unique and targetable clinical characteristics in cancer.

Saturday, March 8 | 8:30 AM – 9:30 AM JST
Poster presentations

Effective immune-based treatment of extraskeletal myxoid chondrosarcoma guided by next-generation gene profiling:

The presentation demonstrates cases of advanced disease with limited treatment options where BostonGene’s comprehensive genomic profiling guided targeted therapy selection.

Thursday, March 6 | 1:05 PM – 1:50 PM JST
Leveraging mappability and analysis of allele frequencies to mitigate false positive germline variant calling:

This study describes BostonGene’s advanced bioinformatic approaches to improve the reliability of germline variant detection in next-generation sequencing analysis.

Friday, March 7 | 2:05 PM – 2:50 PM JST
Evaluating the clinical utility of RNA- and DNA-based comprehensive genomic profiling in patients with advanced cancers:

This large prospective research study describes the diagnostic and clinical utility of BostonGene’s comprehensive genomic profiling in patients with advanced malignancies.

Friday, March 7 | 2:05 PM – 2:50 PM JST
Machine learning (ML)-enabled automation for high-throughput data processing in flow cytometry:

This study highlights BostonGene’s novel machine learning-based cell classification algorithm to significantly reduce turnaround time for analyzing cell populations.

Saturday, March 8 | 1:05 PM – 1:50 PM JST
For more information or to schedule a meeting with BostonGene during the event, please contact Zlata Polyakova at [email protected].